DK1408106T3 - Cancer immunterapi - Google Patents

Cancer immunterapi

Info

Publication number
DK1408106T3
DK1408106T3 DK02022787T DK02022787T DK1408106T3 DK 1408106 T3 DK1408106 T3 DK 1408106T3 DK 02022787 T DK02022787 T DK 02022787T DK 02022787 T DK02022787 T DK 02022787T DK 1408106 T3 DK1408106 T3 DK 1408106T3
Authority
DK
Denmark
Prior art keywords
lymphocytes
sentinel
dukes
nodes
proliferation
Prior art date
Application number
DK02022787T
Other languages
Danish (da)
English (en)
Inventor
Ola Winqvist
Magnus Thoern
Original Assignee
Sentoclone Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sentoclone Ab filed Critical Sentoclone Ab
Application granted granted Critical
Publication of DK1408106T3 publication Critical patent/DK1408106T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0651—Lymph nodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK02022787T 2002-10-11 2002-10-11 Cancer immunterapi DK1408106T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02022787A EP1408106B1 (fr) 2002-10-11 2002-10-11 Immunothérapie du cancer

Publications (1)

Publication Number Publication Date
DK1408106T3 true DK1408106T3 (da) 2007-06-11

Family

ID=32010966

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02022787T DK1408106T3 (da) 2002-10-11 2002-10-11 Cancer immunterapi

Country Status (12)

Country Link
US (1) US8709404B2 (fr)
EP (2) EP1408106B1 (fr)
JP (2) JP5652984B2 (fr)
AT (1) ATE353954T1 (fr)
AU (1) AU2003269760B2 (fr)
CY (1) CY1106573T1 (fr)
DE (1) DE60218173T2 (fr)
DK (1) DK1408106T3 (fr)
ES (1) ES2282355T3 (fr)
NZ (1) NZ539843A (fr)
PT (1) PT1408106E (fr)
WO (1) WO2004032951A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1408106T3 (da) 2002-10-11 2007-06-11 Sentoclone Ab Cancer immunterapi
EP1444989A1 (fr) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensibilisation de cellules à l'apoptose par bloquage selective de cytokines
US20050249699A1 (en) * 2004-05-05 2005-11-10 Stoff Jesse A Immunodynamic complexes and methods for using and preparing such complexes
EA015989B1 (ru) * 2005-08-31 2012-01-30 АйТиЭйч ИММЬЮН ТЕРАПИ ХОЛДИНГЗ АБ Лечение воспалительного заболевания кишечника
US8101173B2 (en) 2005-12-21 2012-01-24 Sentoclone International Ab Method for treating urinary bladder cancer
AU2006328943B2 (en) * 2005-12-21 2011-07-21 Sentoclone International Ab Improved method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer
AU2006328945B2 (en) * 2005-12-21 2011-06-30 Sentoclone International Ab Method for treating malignant melanoma
US8007785B2 (en) 2005-12-21 2011-08-30 Sentoclone International Ab Method for treating colon cancer with tumour-reactive T-lymphocytes
US8211425B2 (en) 2005-12-21 2012-07-03 Sentoclone International Ab Method for treating disseminated cancer
US7951365B2 (en) * 2007-06-27 2011-05-31 Deifiera Falun Ab Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with specific cancer types
DK3156069T3 (da) 2008-06-20 2020-09-21 Univ Duke Sammensætninger, fremgangsmåder, og kits til fremkaldelse af et immunrespons
WO2010006808A1 (fr) * 2008-07-18 2010-01-21 Sentoclone Ab Composition comprenant des lymphocytes t expansés in vitro et inhibiteurs de la formation de vaisseaux appropriés dans le traitement d'un cancer
WO2010083298A1 (fr) * 2009-01-14 2010-07-22 Health Research Inc. Procédés et compositions contenant des inhibiteurs de la mtor pour améliorer les réponses immunitaires
CN110878282A (zh) * 2019-05-09 2020-03-13 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种肿瘤抗原特异性t淋巴细胞的制备方法
AU2022339903A1 (en) 2021-08-30 2025-03-06 Carrygenes Bioengineering, Llc tCD34 AND OTHER MARKERS FOR IDENTIFICATION AND SORTING OF CELLS AND FOR USE AS IN VIVO TRACKING ASSISTANT

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311688A (en) 1979-10-29 1982-01-19 Serono Laboratories Inc. Composition and method for cancer detection in humans
WO1990005183A1 (fr) * 1988-10-31 1990-05-17 Immunex Corporation Recepteurs d'interleukine-4
EP0491851A4 (en) * 1989-09-14 1993-02-17 Cellco, Inc. Method for the production of in vitro expanded lymphoid cells for use in adoptive immunotherapy
US5814295A (en) 1992-04-10 1998-09-29 The Ohio State University Research Foundation Determination of lymph nodes enriched in tumor reactive cells their proliferation and their use in adoptive cellular therapy
US20020182730A1 (en) * 1995-07-26 2002-12-05 Micheal L. Gruenberg Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
AU723355B2 (en) 1996-05-23 2000-08-24 Scripps Research Institute, The MHC class II antigen presenting systems and methods for activating CD4+ T cells
NZ507829A (en) 1998-04-23 2004-03-26 Arch Dev Corp Vaccine adjuvants for immunotherapy of melanoma
AU4603499A (en) 1998-06-26 2000-01-17 Joergen Agnholt Methods of expanding and selecting disease associated t-cells
AU5905400A (en) * 1999-07-14 2001-02-05 Board Of Regents, The University Of Texas System Methods and compositions for delivery and retention of active agents to lymph nodes
GB0007088D0 (en) 2000-03-23 2000-05-17 Torsana A S Detection of immunological memory determining the position of loci of pathologyand therapeutic t-cell conjugates
US7012098B2 (en) 2001-03-23 2006-03-14 Pharmacia Corporation Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
US20030228635A1 (en) * 2002-02-15 2003-12-11 Renovar, Inc. Cell proliferation assays and methods
AU2003258081A1 (en) 2002-08-02 2004-02-23 South Alabama Medical Sciences Foundation Cancer vaccines containing epitopes of oncofetal antigen
EP1560924A4 (fr) 2002-08-16 2006-05-31 Wayne John Cancer Inst Mappage lymphatique moleculaire de ganglions lymphatiques sentinelles
DK1408106T3 (da) 2002-10-11 2007-06-11 Sentoclone Ab Cancer immunterapi
WO2004038029A1 (fr) 2002-10-24 2004-05-06 Dnavec Research Inc. Procede permettant de transferer des genes dans des lymphocytes t
EP1419787A1 (fr) 2002-11-18 2004-05-19 Uwe Prof. Dr. Till Composé destiné à l'identification du ganglion lymphatique
AU2006328945B2 (en) 2005-12-21 2011-06-30 Sentoclone International Ab Method for treating malignant melanoma
US8211425B2 (en) 2005-12-21 2012-07-03 Sentoclone International Ab Method for treating disseminated cancer
AU2006328943B2 (en) 2005-12-21 2011-07-21 Sentoclone International Ab Improved method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer
US8007785B2 (en) 2005-12-21 2011-08-30 Sentoclone International Ab Method for treating colon cancer with tumour-reactive T-lymphocytes
US8101173B2 (en) 2005-12-21 2012-01-24 Sentoclone International Ab Method for treating urinary bladder cancer
US7951365B2 (en) 2007-06-27 2011-05-31 Deifiera Falun Ab Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with specific cancer types
WO2010006808A1 (fr) 2008-07-18 2010-01-21 Sentoclone Ab Composition comprenant des lymphocytes t expansés in vitro et inhibiteurs de la formation de vaisseaux appropriés dans le traitement d'un cancer

Also Published As

Publication number Publication date
CY1106573T1 (el) 2012-01-25
EP1808200A3 (fr) 2007-09-19
NZ539843A (en) 2008-05-30
EP1408106A1 (fr) 2004-04-14
EP1808200A2 (fr) 2007-07-18
US8709404B2 (en) 2014-04-29
AU2003269760B2 (en) 2008-08-28
JP5946282B2 (ja) 2016-07-06
WO2004032951A1 (fr) 2004-04-22
EP1408106B1 (fr) 2007-02-14
JP2006507262A (ja) 2006-03-02
JP2012197260A (ja) 2012-10-18
DE60218173T2 (de) 2007-11-22
AU2003269760A1 (en) 2004-05-04
US20070141026A1 (en) 2007-06-21
ES2282355T3 (es) 2007-10-16
DE60218173D1 (de) 2007-03-29
JP5652984B2 (ja) 2015-01-14
ATE353954T1 (de) 2007-03-15
PT1408106E (pt) 2007-04-30

Similar Documents

Publication Publication Date Title
DE60218173D1 (de) Immuntherapie für Krebs
Chaudhary et al. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs
Bouzidi et al. Prognostic value of natural killer cells besides tumor-infiltrating lymphocytes in breast cancer tissues
Hartmann et al. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN‐α induction in plasmacytoid dendritic cells
Kärjä et al. Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy
Ogura et al. NK cells control tumor-promoting function of neutrophils in mice
AU2006328944B2 (en) Method for treating disseminated cancer
Nakamura et al. TGF-β1 in tumor microenvironments induces immunosuppression in the tumors and sentinel lymph nodes and promotes tumor progression
Tremante et al. A melanoma immune response signature including Human Leukocyte Antigen‐E
Baba et al. Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B
Eggers Autoradiographic and fluorescence antibody studies of the human host immune response to gliomas
Ikeda et al. Multiple malignant melanoma and squamous-cell carcinoma in a burn scar
Mannweiler et al. Colliding/concomitant tumors of the intestine: report of 3 cases
Homma et al. Human leukocyte antigen class I down‐regulation in muscle‐invasive bladder cancer: its association with clinical characteristics and survival after cystectomy
Speiser et al. Disease-driven T cell activation predicts immune responses to vaccination against melanoma
Tsuneyama et al. Expression of MAGE‐A3 in intrahepatic cholangiocarcinoma and its precursor lesions
Osanto et al. Downmodulation of c-myc expression by interferon γ and tumour necrosis factor α precedes growth arrest in human melanoma cells
Domaica et al. Immunomodulation of NK cell activity
Dieckman et al. Activated CD27+ PD-1+ CD8 T cells and CD4 T regulatory cells dominate the tumor microenvironment in refractory celiac disease type II
Hochheiser et al. Tumor reactivity of CD8+ T cells favors acquisition of dysfunctional states in human melanoma.
Fonsatti et al. In vitro analysis of the melanoma/endothelium interaction increasing the release of soluble intercellular adhesion molecule 1 by endothelial cells
Yee Adoptive T cell therapy—immune monitoring and MHC multimers
Kienzler et al. Immune checkpoint inhibitors remodel the immune microenvironment in brain metastases and promote T cell infiltration
Hussein et al. Analysis of the mononuclear inflammatory cell infiltrate in the cirrhotic, dysplastic nodules and hepatocellular carcinomas in patients with chronic hepatitis C infection
Chiplunkar et al. PD. 100 Loss of CD3-zeta chain expression and immune dysfunctions in oral cancer patients